Zero announces three top physicians to Medical Advisory Board May 7, 2019 WASHINGTON, D.C., May 7, 2019 - Three prominent physicians have joined ZERO Prostate Cancer’s Medical Advisory Board. Elisabeth Heath, M.D., F.A.C.P., Rachel S. Rubin, M.D., and Charles J. Ryan, M.D. join ZERO’s esteemed group of leading medical professionals who are dedicated to helping men fight prostate cancer.“All three of our new Medical Advisory Board members are nationally recognized for their work with prostate cancer patients and we were fortunate to feature them as speakers at the 2019 ZERO Prostate Cancer Summit in Washington, D.C. this past February,” said ZERO CEO and President Jamie Bearse. “Bringing these accomplished leaders onto our Medical Advisory Board allows us to tap their expertise year-round to help more patients and their families.”Dr. Heath is the Patricia C. and E. Jan Hartmann endowed chair in Prostate Cancer Research at the Barbara Ann Karmanos Cancer Institute and professor of Oncology and Medicine at Wayne State University School of Medicine in Detroit, Michigan. Dr. Heath has more than 26 years of experience and is a leading patient advocate for the metro Detroit community. At the ZERO Prostate Cancer Summit, she spoke about funding clinical trials and how that translates into better care for prostate cancer patients.Dr. Rubin is a urologic surgeon and fellowship-trained sexual medicine specialist. She believes in comprehensive, multidisciplinary and customized care for patients and their partners suffering from sexual dysfunction. Her expertise includes erectile dysfunction, pelvic pain, penile curvature, low testosterone, low libido, urinary incontinence, and penile implants. Dr. Rubin is with IntimMedicine Specialists in Washington, D.C.Dr. Ryan is Director of Hematology, Oncology and Transplantation at the University of Minnesota. His research is aimed at developing new therapies for patients with advanced and recurrent prostate cancer. Specifically, Dr. Ryan is focused on the development of new hormonal and targeted therapies for prostate cancer, biomarkers defining disease aggressiveness, and strategies to maximize survivorship for men on long-term treatment.“These three doctors will help grow ZERO’s patient support programs and educational resources aimed at ensuring all prostate cancer patients get the support and information they need,” said ZERO CEO and President Jamie Bearse. “We’re honored to have them as part of the ZERO family.”These new Medical Advisory Board members join current board members Alicia Morgans, M.D., M.P.H. (Chair), Tomasz Beer, M.D., Leo Giambarresi, Ph.D., Joanna Morales, Esq., Meredith Morgan, MSN, Kelvin Moses, M.D., Ph.D., Alison Sachs, MSW, CSW, OSW-C, Eric Shinohara, M.D., MSCI, Nilay M. Gandhi, M.D., Benjamin H. Lowentritt, M.D., F.A.C.S., and Gary M. Kirsh, M.D. About ZERO Prostate CancerZERO Prostate Cancer (ZERO) is on a mission to improve and save lives from prostate cancer through advocacy, education, awareness, and support. Formerly known as the National Prostate Cancer Coalition, ZERO was founded in 1996 to stand up for people impacted by prostate cancer. Today, ZERO serves as the nation's leading prostate cancer organization, advancing a future where prostate cancer detection is early, support is unwavering, and care is accessible to all. For over 30 years, ZERO has led the way in prostate cancer advocacy, screenings, and partnerships, successfully unlocking funding toward breakthrough discoveries, treatments, and lifesaving access to care. As the nation’s #1 provider of prostate cancer resources, programs, and services, ZERO has supported millions of people at-risk or diagnosed, and their families. As the voice of the prostate cancer community, ZERO's urgent focus on breaking barriers to survival—by closing gaps in diagnosis, treatment, and care—brings critical attention to those most likely to be impacted by this disease. Learn more at ZEROcancer.org About ZERO Press Release More for you
WASHINGTON, D.C., May 7, 2019 - Three prominent physicians have joined ZERO Prostate Cancer’s Medical Advisory Board. Elisabeth Heath, M.D., F.A.C.P., Rachel S. Rubin, M.D., and Charles J. Ryan, M.D. join ZERO’s esteemed group of leading medical professionals who are dedicated to helping men fight prostate cancer.“All three of our new Medical Advisory Board members are nationally recognized for their work with prostate cancer patients and we were fortunate to feature them as speakers at the 2019 ZERO Prostate Cancer Summit in Washington, D.C. this past February,” said ZERO CEO and President Jamie Bearse. “Bringing these accomplished leaders onto our Medical Advisory Board allows us to tap their expertise year-round to help more patients and their families.”Dr. Heath is the Patricia C. and E. Jan Hartmann endowed chair in Prostate Cancer Research at the Barbara Ann Karmanos Cancer Institute and professor of Oncology and Medicine at Wayne State University School of Medicine in Detroit, Michigan. Dr. Heath has more than 26 years of experience and is a leading patient advocate for the metro Detroit community. At the ZERO Prostate Cancer Summit, she spoke about funding clinical trials and how that translates into better care for prostate cancer patients.Dr. Rubin is a urologic surgeon and fellowship-trained sexual medicine specialist. She believes in comprehensive, multidisciplinary and customized care for patients and their partners suffering from sexual dysfunction. Her expertise includes erectile dysfunction, pelvic pain, penile curvature, low testosterone, low libido, urinary incontinence, and penile implants. Dr. Rubin is with IntimMedicine Specialists in Washington, D.C.Dr. Ryan is Director of Hematology, Oncology and Transplantation at the University of Minnesota. His research is aimed at developing new therapies for patients with advanced and recurrent prostate cancer. Specifically, Dr. Ryan is focused on the development of new hormonal and targeted therapies for prostate cancer, biomarkers defining disease aggressiveness, and strategies to maximize survivorship for men on long-term treatment.“These three doctors will help grow ZERO’s patient support programs and educational resources aimed at ensuring all prostate cancer patients get the support and information they need,” said ZERO CEO and President Jamie Bearse. “We’re honored to have them as part of the ZERO family.”These new Medical Advisory Board members join current board members Alicia Morgans, M.D., M.P.H. (Chair), Tomasz Beer, M.D., Leo Giambarresi, Ph.D., Joanna Morales, Esq., Meredith Morgan, MSN, Kelvin Moses, M.D., Ph.D., Alison Sachs, MSW, CSW, OSW-C, Eric Shinohara, M.D., MSCI, Nilay M. Gandhi, M.D., Benjamin H. Lowentritt, M.D., F.A.C.S., and Gary M. Kirsh, M.D.
About ZERO Prostate CancerZERO Prostate Cancer (ZERO) is on a mission to improve and save lives from prostate cancer through advocacy, education, awareness, and support. Formerly known as the National Prostate Cancer Coalition, ZERO was founded in 1996 to stand up for people impacted by prostate cancer. Today, ZERO serves as the nation's leading prostate cancer organization, advancing a future where prostate cancer detection is early, support is unwavering, and care is accessible to all. For over 30 years, ZERO has led the way in prostate cancer advocacy, screenings, and partnerships, successfully unlocking funding toward breakthrough discoveries, treatments, and lifesaving access to care. As the nation’s #1 provider of prostate cancer resources, programs, and services, ZERO has supported millions of people at-risk or diagnosed, and their families. As the voice of the prostate cancer community, ZERO's urgent focus on breaking barriers to survival—by closing gaps in diagnosis, treatment, and care—brings critical attention to those most likely to be impacted by this disease. Learn more at ZEROcancer.org
